| Reporting Organization: | McGill University |
|---|---|
| Total Budget ($CAD): | $ 50,000 |
| Timeframe: | May 30, 2017 - February 1, 2019 |
| Status: | Implementation |
| Contact Information: |
Julia von Oettingen [email protected] |
Unspecified
| Haiti - $ 50,000.00 (100.00%) | |
|
|
|
| Health Systems, Training & Infrastructure (25 %) | |
|
|
|
| Newborn & Child Health (25 %) | |
|
|
|
| Non-Communicable Diseases (25 %) | |
|
|
|
| Reproductive Health & Rights incl. Maternal Health (25 %) | |
|
|
|
Unspecified
Return to top| Gender and age: | Adult women Adolescent females Newborns |
|---|---|
| Descriptors: | Other Pregnant women, women of reproductive age living in the Artibonite region |
| Total Direct Population: | Unspecified |
| Clinics built | |
| Research conducted | |
| Training conducted |
1) Develop and implement a screening strategy to measure the prevalence of Gestational Diabetes (GD) and Gestational Hypertension (GHTN) and preeclampsia in Haiti.
2) Determine the proportion of Haitian women with GHTN, Preeclampsia, or GD.
3) Develop a strategy for dealing with these conditions.
4) Determine the impact of these diseases on pregnancy outcomes as well as neonatal outcomes.
5) Validate a questionnaire for Peripartum cardiomyopathy (PPCM) screening.
700 participants were enrolled in the study between 24-28 weeks of gestation, and followed until delivery. The prevalence of pre-existing and gestational DM in Haiti was lower than the estimated worldwide rate of hyperglycemia in pregnancy. Preeclampsia, however, may have
affected up to three times more women in Haiti than globally. Study DYAMAN proves that implementation of screening and management protocols for hypertensive disorders and diabetes in pregnancy is feasible in Haiti. Research is required to understand barriers to patient attendance at antenatal follow-up, treatment escalation for hyperglycemia, and in-hospital delivery.
